Skip to main content
. Author manuscript; available in PMC: 2021 Oct 13.
Published in final edited form as: J Clin Lipidol. 2018 Apr 3;12(4):981–987. doi: 10.1016/j.jacl.2018.03.089

Table 2.

Anthropometric and metabolic characteristics of NAFLD study population by abnormal TG and non–HDL-C

Variables Elevated TG (n = 170) Normal (n = 24) P value Elevated non-HDL-C (n = 113) Normal (n = 83) P value
Weight, kg 91.1 (35.8) 95.8 (49.2) .58 92.8 (33.2) 90.3 (42.9) .64
Height, cm 158.0 (16.1) 160.4 (15.4) .51 159.5 (14.7) 156.6 (17.6) .22
BMI
 BMI, kg/m2 35.3 (9.2) 36.4 (13.7) .63 35.5 (8.6) 35.4 (11.1) .93
 BMI percentile 98.7 (2.5) 95.8 (10.9) .0038 98.6 (2.8) 98.0 (5.9) .31
SystoLic BP, mm Hg 122.5 (14.1) 124.9 (18.7) .56 124.7 (14.1) 120.3 (14.9) .09
DiastoLic BP, mm Hg 66.9 (9.9) 67.1 (11.1) .94 67.8 (10.7) 65.6 (8.9) .23
Liver enzymes, U/L
 ALT 90.5 (64.0) 56.0 (35.8) .01 94.0 (66.3) 74.9 (54.3) .03
 AST 61.3 (45.4) 44.7 (18.8) .08 61.6 (43.5) 55.8 (42.9) .35
 GGT 50.1 (39.9) 30.2 (19.3) .035 53.9 (43.4) 38.4 (27.6) .02
InsuLin, mIU/L 47.0 (41.9) 34.1 (19.8) .35 45.1 (39.4) 45.3 (40.8) .98
HbA1c, % 5.9 (1.6) 6.0 (2.1) .90 6.0 (1.6) 5.9 (1.7) .65
TotaL choLesteroL, mg/dL 173.6 (33.5) 139.4 (21.1) <.0001 191.0 (27.3) 140.8 (16.6) <.0001
Non-HDL-C, mg/dL 134.8 (32.3) 92.8 (20.9) <.0001 153.3 (25.9) 99.2 (15.8) <.0001
HDL-C, mg/dL 38.8 (9.1) 46.6 (10.3) .0001 38.4 (9.5) 41.5 (9.5) .03
LDL-C, mg/dL 104.9 (29.4) 79.0 (21.2) <.0001 119.9 (23.4) 77.5 (17.3) <.0001
TrigLycerides, mg/dL 201.7 (97.8) 62.5 (17.5) <.0001 220.5 (104.8) 136.2 (77.0) <.0001

NAFLD, nonalcoholic fatty liver disease; TG, triglyceride; non–HDL-C, non–high-density lipoprotein cholesterol; BMI, body mass index; BP, blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

Data are presented as mean (standard deviation).

Significance considered at P ≤ .05 and is in bold.